Nautilus Biotechnology, Inc. NAUT
At closeNov 3, 2026, 6:22 PM EST
After hours · Nov 3, 6:22 PM ET
- YTD
- +20.51%
- 1 year
- +27.03%
- Market cap
- 299.33M
- EPS (ttm)
- -0.46
- Shares out
- 125.56M
- Forward P/E
- -2.32
- YTD return
- +20.51%
- 1-year return
- +27.03%
- Volume
- 4.75M
- Avg volume
- 5.45M
- Open
- 2.40
- Previous close
- 2.34
- Day's range
- 2.32 – 2.55
- 52-week range
- 0.841 – 4.31
- Beta
- 1.04
- Analysts
- Buy
- Price target
- 3.44 (+46.3%)
- Earnings date
- Jul 30, 2024
2Y -0.22 (-8.56%)
Key statistics
- Enterprise value
- 111.95M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.97
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -35.00M
- Total cash
- 140.61M
- Total debt
- 31.57M
- Return on equity
- -28.04%
- Short % of float
- 2.81%
- 50-day average
- 2.42
- 200-day average
- 2.56
Analyst view
Consensus: buy
- Target (low)
- 1.75
- Target (mean)
- 3.44
- Target (high)
- 5.00
- Strong buy0
- Buy2
- Hold2
- Sell0
- Strong sell1
Next earnings
Jul 30, 2024
Expected Jul 30, 2024. Consensus EPS estimate -0.16333.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 29, 2024 | Sep 1, 2024 | -0.17 | -0.13 | +0.04 | +23.53% |
| Jul 30, 2024 | Jun 1, 2024 | -0.16 | -0.14 | +0.02 | +12.50% |
| Jul 30, 2024 | Jun 1, 2024 | -0.16 | — | — | — |
| Apr 30, 2024 | Mar 1, 2024 | -0.16 | -0.15 | +0.01 | +6.25% |
| Apr 30, 2024 | Mar 1, 2024 | -0.16 | — | — | — |
| Feb 28, 2024 | Dec 1, 2023 | -0.16 | -0.14 | +0.02 | +12.50% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Goldman Sachs | down | Neutral | Sell |
| Jun 27, 2024 | Guggenheim | init | — | Buy |
| Aug 3, 2023 | Morgan Stanley | reit | Equal-Weight | Equal-Weight |
| Aug 3, 2022 | Morgan Stanley | main | — | Equal-Weight |
| Aug 3, 2022 | Goldman Sachs | main | — | Neutral |
| Jul 14, 2022 | Goldman Sachs | main | — | Neutral |
About Nautilus Biotechnology, Inc.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nautilus.bio
News
Nautilus Biotechnology: Bullish On Voyager's Upcoming Launch 
Nautilus Biotechnology, Inc. (NAUT) Q3 2026 Earnings Call Transcript 
Nautilus Biotechnology Q3 Earnings Call Highlights 
Nautilus Biotechnology Q3 2026 Earnings Call Transcript 
Nautilus Biotechnology Announces Participation In SEEDS Research Consortium, Which Was Awarded Up To $51.7M By The Advanced Research Projects Agency For Health 
Nautilus Biotechnology Reports Third Quarter 2026 Financial Results 
Nautilus to Measure Proteoforms Driving Alzheimer's Disease and Cancer in ARPA-H-Funded SEEDS Consortium 
12 Health Care Stocks Moving In Monday's Intraday Session 
12 Health Care Stocks Moving In Friday's Intraday Session 
Winnebago Industries Posts Upbeat Q4 Earnings, Joins SpaceX, Super Micro Computer And Other Big Stocks Moving Higher On Wednesday
Your note
Sign in to keep a note on NAUT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GODWIN MARY E | Officer | Conversion of Exercise of derivative security | Sep 22, 2024 | 0 |
| PATEL SUJAL M | Chief Executive Officer | Purchase | Mar 10, 2024 | 17,159,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Ah Capital Management, L.L.C. | 14.06% | 17,653,917 | 30.36M | Sep 29, 2024 |
| Perceptive Advisors Llc | 10.03% | 12,594,211 | 21.66M | Sep 29, 2024 |
| Cercano Management Llc | 5.71% | 7,172,985 | 12.34M | Sep 29, 2024 |
| Madrona Venture Group, LLC | 4.79% | 6,020,770 | 10.36M | Sep 29, 2024 |
| Blackrock Inc. | 2.84% | 3,565,243 | 6.13M | Sep 29, 2024 |
| Vanguard Group Inc | 2.20% | 2,766,343 | 4.76M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.39% | 1,745,090 | 3.00M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 0.96% | 1,202,875 | 2.07M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.53% | 670,132 | 1.15M | Sep 29, 2024 |
| iShares Biotechnology ETF | 0.41% | 519,943 | 894.30K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.39% | 491,428 | 845.26K | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.35% | 433,685 | 745.94K | Oct 30, 2024 |